Received Sep 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | IM |
She is requesting advice on which pain relief she can use without affecting the effectiveness of the vaccine; she is currently experiencing the usual side effects; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (She is requesting advice on which pain relief she can use without affecting the effectiveness of the vaccine) and IMMUNISATION REACTION (she is currently experiencing the usual side effects) in a female patient of an unknown age who received mRNA-1273.251 (Spikevax LP.8.1 PFS) for COVID-19 prophylaxis. No Medical History information was reported. On 10-Sep-2025, the patient received dose of mRNA-1273.251 (Spikevax LP.8.1 PFS) (Intramuscular use) 1 dosage form. In September 2025, the patient experienced PAIN (She is requesting advice on which pain relief she can use without affecting the effectiveness of the vaccine) and IMMUNISATION REACTION (she is currently experiencing the usual side effects). At the time of the report, PAIN (She is requesting advice on which pain relief she can use without affecting the effectiveness of the vaccine) and IMMUNISATION REACTION (she is currently experiencing the usual side effects) outcome was unknown. No concomitant medication was reported. The patient had received the Spikevax vaccine on 10-Sep-2025 and shared that she experienced the usual side effects. She requested advice on which pain relief she could use without affecting the effectiveness of the vaccine. It was unknown if the patient experienced any additional symptoms/events. Reporter causality was not reported. No treatment medication was reported. Reporter did not allow further contact